Share this article
Share this article
CROWN POINT, Ind., May 17, 2021 /PRNewswire/ Neurodon Corporation today announced that the company has initiated the essential studies necessary to enable preparation of an Investigational New Drug (IND) application for the U.S. Food and Drug Administration (FDA) for NDC-0009, a novel small molecule to treat T1D. Neurodon aims to initiate a Phase 1 clinical trial in the second half of 2022 or early 2023. We are excited to achieve this milestone with the selection of a development candidate for our diabetes program. Our molecules have demonstrated compelling efficacy in both animal models and human pancreatic islets, and we are focused on developing first-in-class therapeutics to meaningfully impact those living with T1D, said Neurodon CEO, Russell Dahl, Ph.D. We look forward to translating our drug s ability to protect and restore insulin production in pancreatic islet cells to provide disease-modifying options for patients.